The News Review:
- UQ leads the way on complementary medicine research
- LIFE Biosystems to Provide Strategic IT Consulting to MD Anderson…
- Stem cell first for heart attack victims
- Health calendar
- UMass Medical School researchers awarded pediatric HIV vaccine…
- VistaGen Collaborates with Canadian US and British Researchers To…
UQ leads the way on complementary medicine research
EurekAlert – EurekAlert (press release) – Apr 23, 2008
” “We have got a profile in this area already and this new initiative will give UQ a very important presence as a central point for complementary medicine research” he said. In other NHMRC funding Dr Jon Adams from UQ’s School of Population Health was awarded $450771 in a Complementary and Alternative Medicine (CAM) Grant to look at CAM use among mid-age women across the urban-rural divide. Two other UQ researchers from the School of Medicine have received more than $1 million under the NHMRC’s General Practice Clinical Research Program. Associate Professor Jenny Doust received $457200 for a project to look at improving risk assessment to prevent cardiovascular disease and Associate Professor Geoff Mitchell received $561670 to look at different ways of supporting the needs of carers of patients with advanced cancer.
LIFE Biosystems to Provide Strategic IT Consulting to MD Anderson…
Earthtimes – Apr 23, 2008
Anderson to help design plan and organize the replacement of the existing Clinical Trial Protocol Data Management System (PDMS) with an updated Comprehensive Protocol Management Solution. Financial terms of the agreement were not disclosed. “In order to sustain the high standards of clinical research being conducted at M. Anderson it is important for our clinical research information systems to be able to meet the demands of our research community” said Dr. Maurie Markman Vice President of Clinical Research for M… CE of LIFE Biosystems. “ur expertise in clinical research information systems will strengthen their research processes and provide the infrastructure to support their needs into the future. ” About LIFE Biosystems LIFE Biosystems is an in silico discovery company focusing on the unmet therapeutic needs of clinical oncology. Working together with the biopharmaceutical industry and comprehensive cancer centers we strive to address the key issues facing clinical oncology research and therapeutic development today. As expert practitioners of in silico discovery in molecular medicine our goal is to transform patient information and molecular data into a new level of clinical discovery intellectual property and ultimately patient benefit. For additional information about the company please visit:.
Stem cell first for heart attack victims
Telegraph.co.uk – Apr 23, 2008
This the first clinical research project to be supported by the UK Stem Cell Foundation was designed by Dr Anthony Mathur senior lecturer and consultant cardiologist and Prof John Martin British Heart Foundation chair in cardiovascular sciences; at Barts and the London NHS Trust and University College London respectively. The men were among the heart attack patients brought to the London Chest Hospital (Barts and the London NHS Trust) and the Heart Hospital (UCLH Trust) for treatment. In the procedure a stem cell sample is taken from the patient’s own bone marrow. After the stem cells have been prepared they are injected into the previously blocked artery. The stem cells were injected in conjunction with angioplasty – where the blocked arteries in heart attack patients are opened as quickly as possible with a balloon.
Health calendar
Pittsburgh Post-Gazette – Pittsburgh Post Gazette – Apr 23, 2008
• The Foundation for Clinical Research and IBD is sponsoring a patient education seminar “Advances in Inflammatory Bowel Disease: 2008″ from 6 to 9 p. April 29 at the Holiday Inn 4859 McKnight Road Ross. Featured speakers are Drs. Asher Kornbluth associate clinical professor of medicine at the Mount Sinai School of Medicine; Miguel Regueiro co-director of Inflammatory Bowel Disease Center and director of the GI Hepatology and Nutrition Fellowship through the University of Pittsburgh Medical Center; and Cheryl Blank assistant professor of pediatric gastroenterology at Children’s Hospital of Pittsburgh.
UMass Medical School researchers awarded pediatric HIV vaccine…
Genetic Engineering News – Genetic Engineering News (press release) – Apr 23, 2008
Shan Lu MD PhD professor of medicine at the University of Massachusetts Medical School (UMMS) and colleague Katherine Ruiz De Luzuriaga MD professor of pediatrics and director of the division of pediatric immunology are among the first five recipient teams to receive a Pediatric HIV Vaccine Research Program grant. The UMMS team was chosen from 46 teams that competed for the grants; other awardees include researchers at Massachusetts General Hospital; Childrens Hospital Los Angeles; Beth Israel Deaconess Medical Center; and the University of Colorado Health Science Center. The EGPAF Pediatric HIV Vaccine Research Program supports basic and pre-clinical research relevant to pediatric HIV vaccine design and development. The program was created after a survey of global HIV vaccine projects found that pediatric issues were virtually absent in the research agenda. With a global network of scientists and a long history of supporting pediatric-focused basic research the Foundation is well positioned to address this gap. ne potentially promising way to reduce the spread of HIV is through a preventive vaccine that will protect all peopleincluding infantsfrom the virus. Vaccines have reduced many common childhood infections by up to 99 percent in the developed world and may be the single most effective public health measure.
VistaGen Collaborates with Canadian US and British Researchers To…
Earthtimes – Apr 23, 2008
Gordon Keller director of Toronto’s McEwen Centre for Regenerative Medicine — the stem cell research arm of the University Health Network (UHN). ther collaborators in the landmark cardiac cell study included scientists from the Mount Sinai School of Medicine Indiana University School of Medicine the Weill Medical College of Cornell University and London’s Kings College Department of Infectious Diseases. “This development means that we can efficiently and accurately make different types of human heart cells for use in both basic and clinical research” Dr. He added “In the future these cells may also be very effective in testing how they respond to different drugs and in developing new strategies for repairing damaged hearts following a heart attack. ” The study created the cardiac cells by supplying embryonic stem cell cultures with a “cocktail” of growth factors involved in heart development and then used surface markers to identify a unique precursor cell that is committed to heart development. By isolating this novel cardiac stem cell and supplying the right growth factors at the right time during development they encouraged the cells to grow into three different types of cells — cardiomyocytes endothelial cells and vascular smooth muscle cells — each an important constituent of the cardiovascular system.
